Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-NOTA-RM26 PET/CT in Glioma
NCT06412952Phase 1Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Oct 2022
- Primary completion
- May 2024
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 68Ga-NOTA-RM26 in glioma, sponsored by Peking Union Medical College Hospital. Primary endpoint: Maximum Standardized Uptake Value at 1.5 years. Started Oct 2022; status: recruiting.
02
Drugs
68Ga-NOTA-RM26
03
Conditions
glioma
Beyond the preview
Go deeper on NCT06412952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06412952.